Clinical, Cytological, Histological and Immunohistochemical Features of Cutaneous Mast Cell Tumours in Ferrets ( Mustela putorius furo )

Vilalta, Laura; Meléndez-Lazo, Antonio; Doria, G.; Ramis, A.; Solano‐Gallego, Laia; Pastor, Josep; Martorell, Jaime

doi:10.1016/j.jcpa.2016.07.012

Cited by 13 publications

(13 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The discrepancy in Toluidine blue staining between cytology and histology in ferret MCTs is confusing and could lead to misdiagnosis. In the same study, all tumours had either cytoplasmic or membrane immunostaining with Kit (Vilalta et al, ). As would be expected from the lack of reported tumour recurrence or metastasis, there was no relationship between Kit immunostaining and prognosis (Vilalta et al, ).…”

Section: Mast Cell Neoplasia In Other Animalsmentioning

confidence: 97%

“…In one study of 15 tumours from 10 ferrets, neither haematoxylin and eosin nor Toluidine blue staining detected mast cell granules in histologic sections (Vilalta et al, ). However, in cytologic preparations of 12 tumours stained with Toluidine blue or Wright's–Giemsa stains, metachromatic granules were visualized in all cases, but not in any case stained with Modified Wright's stain (Vilalta et al, ). The discrepancy in Toluidine blue staining between cytology and histology in ferret MCTs is confusing and could lead to misdiagnosis.…”

Section: Mast Cell Neoplasia In Other Animalsmentioning

confidence: 99%

“…Mast cell tumours represent up to 44% of all cutaneous and subcutaneous neoplasms in ferrets (Avallone et al, ). The tumours are typically benign and neither local recurrence after surgical excision nor metastatic disease has been reported (Vilalta et al, ). Histologically, most ferret MCTs consist of well‐differentiated mast cells where mitotic figures are rare and, similar to cats, few eosinophils are present (Vilalta et al, ).…”

Section: Mast Cell Neoplasia In Other Animalsmentioning

confidence: 99%

“…The tumours are typically benign and neither local recurrence after surgical excision nor metastatic disease has been reported (Vilalta et al, ). Histologically, most ferret MCTs consist of well‐differentiated mast cells where mitotic figures are rare and, similar to cats, few eosinophils are present (Vilalta et al, ). In one study of 15 tumours from 10 ferrets, neither haematoxylin and eosin nor Toluidine blue staining detected mast cell granules in histologic sections (Vilalta et al, ).…”

Section: Mast Cell Neoplasia In Other Animalsmentioning

confidence: 99%

“…Mast cell tumours represent up to 44% of all cutaneous and subcutaneous neoplasms in ferrets (Avallone et al, 2016). The tumours are typically benign and neither local recurrence after surgical excision nor metastatic disease has been reported (Vilalta et al, 2016).…”

Section: Ferret (Mustela Putorius Furo)mentioning

confidence: 99%

See 4 more Smart Citations

Comparative aspects of mast cell neoplasia in animals and the role of KIT in prognosis and treatment

Tamlin

Bottema

Peaston

2019

Veterinary Medicine & Sci

View full text Add to dashboard Cite

Mast cell neoplasia clinical presentation and biological behaviour vary considerably across mammalian species, ranging from a solitary benign mass to an aggressive systemic malignancy. Mutations in the KIT Proto‐Oncogene Receptor Tyrosine Kinase (KIT) gene are common molecular abnormalities involved in mast cell tumorigenesis. KIT mutations often occur in dog, cat and human neoplastic mast cells and result in altered Kit protein structure and function. In dogs, certain KIT mutations are associated with more malignant and lethal disease. In contrast, KIT mutations in feline and human mast cell neoplasms are not correlated with prognosis, but are of value in diagnosis and treatment planning in humans. KIT genetic abnormalities have not been well investigated in other species, although aberrant cytoplasmic Kit protein staining detected in neoplasms of the ferret, horse and cow resembles aberrant Kit staining patterns detected in neoplastic mast cells of dogs, cats and humans. Mutations within KIT are classified as either regulatory‐type or enzymatic pocket‐type mutations according to their location within the KIT Proto‐Oncogene. Mutations within the enzymatic pocket domain confer tumour resistance to tyrosine kinase inhibitors (TKIs). Hence, knowledge of tumour KIT mutation status adds valuable information for optimizing patient treatment strategies. The use of TKIs in combination with conventional chemotherapeutics has opened a new treatment avenue for patients unresponsive to existing drugs. This review highlights the similarities and differences of mast cell neoplasia in mammals with a special focus on the involvement of KIT in the canine and feline forms in comparison to human mast cell neoplasia.

show abstract

Section: Mast Cell Neoplasia In Other Animalsmentioning

confidence: 97%

Section: Mast Cell Neoplasia In Other Animalsmentioning

confidence: 99%